Biosimilar Labeling: FDA Says Leave Comparability Data Out
This article was originally published in The Pink Sheet Daily
Executive Summary
Data developed to show no clinically meaningful differences with the reference product could confuse prescribers, agency says in new draft guidance.
You may also be interested in...
Biosimilar Labeling: US FDA’s Final Guidance Means Status Quo For Sponsors
Advice document, little changed from a March 2016 draft, continues to reflect agency’s view that clinical studies supporting a demonstration of biosimilarity should not be included in labeling.
Biosimilar Labeling: US FDA’s Final Guidance Means Status Quo For Sponsors
Advice document, little changed from a March 2016 draft, continues to reflect agency’s view that clinical studies supporting a demonstration of biosimilarity should not be included in labeling.
Biosimilar User Fee Agreement Puts FDA On Hook For Delayed Guidances
Draft guidelines on interchangeability and statistical considerations due by end of 2017, suggesting long-awaited documents may not see the light of day this year as many had hoped.